Efficacy and safety of autologous platelet rich plasma for the treatment of vascular ulcers in primary care: Phase III study

Abstract

BackgroundVascular ulcers are commonly seen in daily practice at all levels of care and have great impact at personal, professional and social levels with a high cost in terms of human and material resources. Given that the application of autologous platelet rich plasma has been shown to decrease healing times in various different studies in the hospital setting, we considered that it would be interesting to assess the efficacy and feasibility of this treatment in primary care. The objectives of this study are to assess the potential efficacy and safety of autologous platelet rich plasma for the treatment of venous ulcers compared to the conventional treatment (moist wound care) in primary care patients with chronic venous insufficiency (C, clinical class, E, aetiology, A, anatomy and P, pathophysiology classification C6).DesignWe will conduct a phase III, open-label, parallel-group, multicentre, randomized study. The subjects will be 150 patients aged between 40 and 100 years of age with an at least 2-month history of a vascular venous ulcer assigned to ten primary care centres. For the treatment with autologous platelet rich plasma, all the following tasks will be performed in the primary care setting: blood collection, centrifugation, separation of platelet rich plasma, activation of coagulation adding calcium chloride and application of the PRP topically after gelification. The control group will receive standard moist wound care. The outcome variables to be measured at baseline, and at weeks 5 and 9 later include: reduction in the ulcer area, Chronic Venous Insufficiency Quality of Life Questionnaire score, and percentage of patients who require wound care only once a week.DiscussionThe results of this study will be useful to improve the protocol for using platelet rich plasma in chronic vascular ulcers and to favour wider use of this treatment in primary care.Trial registrationCurrent Controlled Trials NCT02213952

Platelet-rich plasma exhibits beneficial effects for rheumatoid arthritis mice by suppressing inflammatory factors

“…PRP has been reported to be associated with numerous human diseases; in joint diseases, the application of autologous PRP has been observed to lead to decreased healing times in various clinical cases (28)(29)(30). In addition, a previous report suggested that the efficacy and feasibility of PRP treatment was notable in RA and avascular necrosis (31). However, although the application of PRP in the laboratory and in clinical practice has exhibited positive outcomes, the use of PRP has remained controversial, particularly its application as a treatment for RA and ankle cartilage pathology (32).…”

valuation of Safety and Preliminary Effectiveness of Point-of-Care Cell Processing System: An Observational Study

“…Platelet rich plasma (PRP) is defined as a rich suspension of platelets in plasma derived from whole blood that has 2-6 fold higher platelet concentrate [26]. Platelets are a reservoir of proteins known as growth factors including platelet derived growth factor (PDGF), transforming growth factor-β (TGF-β), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), insulin like growth factor-1 (IGF-1), and fibroblastic growth factor (FGF).…”

The Efficacy of Platelet-Rich Donor Plasma for the Topical Treatment of Venous Trophic Ulcers

“…(14)(15)(16) Several studies using this technique have demonstrated adecrease in healing time compared to conventional treatments (in particular, the currently recommended MWC). Releasing cytokines and hemostatic factors into the tissue of the growth factors, after the destruction of platelets, induces chemotaxis of the major cell types participating in the repair processes.…”